Economic evaluation of letrozole in the treatment of advanced breast cancer in postmenopausal women in Canada

Value in Health

Volumn 3, Issue 1, 2000, Pages 31-39

  Nuijten, Mark ^a,d   McCormick, John ^b   Waibel, Franz ^c   Parison, Diana ^b  

^a Medtap   (Netherlands)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Novartis Pharma Canada Inc ^*  (Netherlands)

Author keywords

Advanced breast cancer; Canada; Cost effectiveness ratio; Letrozole; Markov modeling

Indexed keywords

LETROZOLE; MEGESTROL ACETATE;

ARTICLE; BREAST CANCER; CANADA; CANCER HORMONE THERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0034058430     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2000.31004.x     Document Type: Article

References (39)

1. JR Harris ME Lippman U Veronesi W Willett Breast cancer N Engl J Med 327 1992 319 328
2. JF Forbes The control of breast cancer: the role of tamoxifen Sem Oncol 24 Suppl. 1 1997 S1 19
3. National Cancer Institute of Canada Canadian Cancer Statistics 1998 Statistics Canada Ottawa
4. C Henderson Breast cancer KJ Isselbacher Harrison's Principles of Internal Medicine 13th ed. 1994 McGraw-Hill, Inc. New York
5. HE Bryant PMA Brasher Risks and probabilities of breast cancer: short-term versus lifetime probabilities Can Med Assoc J 150 1994 211 216
6. BP Will J-M Berthelot C Houle A model for estimating the costs and burdens of breast cancer diagnosis and treatment in Canada Health Reports 5 1993 399 408
7. RD Rubens Management of early breast cancer BMJ 304 1992 1361 1364
8. SM O'reilly RS Camplejohn DM Barnes Node negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry J Clin Oncol 8 1990 2040 2060
9. RD Rubens Key issues in the treatment of advanced breast cancer: expectations and outcomes Pharmacoeconomics 9 Suppl. 2 1996 1 7
10. JF Corry PE Lonning Systematic therapy in advanced breast cancer; efficacy and cost utility Pharmacoeconomics 5 1994 198 212
11. BE Hillner TJ Smith CE Desch Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model Breast Can Res Treat 25 1993 97 105
12. BE Hillner TJ Smith Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer N Engl J Med 324 1991 160 168
13. J Hutton R Brown M Borowitz A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer Pharmacoeconomics 9 Suppl. 2 1996 8 22
14. HT Mouridsen Systemic therapy of advanced breast cancer Drugs 44 Suppl. 4 1992 17 28
15. CI Falkson G Falkson HC Falkson Postmenopausal breast cancer. Drug therapy in the 1990s Drugs Aging 3 1993 106 121
16. RD Gelber BF Cole A Goldhirsch Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival Lancet 347 1996 1066 1071
17. SF Hurley RM Huggins RD Snyder JF Bishop The cost of breast cancer recurrences Br J Cancer 65 1992 449 455
18. MA Richards S Braysher WM Gregory RD Rubens Advanced breast cancer: use of resources and cost implications Br J Cancer 67 1993 856 860
19. HJ de Koning BM van Ineveld GJ van Oortmarssen Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors Int J Cancer 49 1991 531 537
20. HJ de Koning BM van Ineveld JCJM de Haes Advanced breast cancer and its prevention by screening Br J Cancer 65 1992 950 955
21. P Dombernowsky I Smith G Falkson Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose-effect and improved efficacy and tolerability compared with megestrol acetate J Clin Oncol 16 1998 453 461
22. JR Beck SG Pauker The Markov process in medical diagnosis Med Dec Making 3 1983 419 458
23. MJC Nuijten I Meester F Waibel S Wait Cost-effectiveness of letrozole in the treatment of advanced breast cancer in post-menopausal women in the UK Pharmacoeconomics 16 4 1999 379 397
24. DK Miller SM Homan Determining transition probabilities: confusion and suggestions Med Dec Making 1 1994 52 58
25. C Evans The use of consensus methods and expert panels in pharmacoeconomic studies. Practical applications and methodological shortcomings Pharmacoeconomics 12 1997 121 129
26. MC Weinstein HV Fineberg Clinical Decision Analysis 1980 W.B. Saunders Company Toronto
27. TO Tengs ME Adams JS Pliskin Five hundred life-saving interventions and their cost-effectiveness Risk Anal 15 1995 369 390
28. A Covens S Boucher K Roche Is paclitaxel and cisplatin a cost-effective first-line therapy for advanced ovarian carcinoma? Cancer 77 1996 2086 2099
29. E Garcia-Giralt Y Ayme M Carton Second and third-line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen Breast Can Res Treatment 24 1992 139 145
30. TJ Iveson J Ahern TE Smith Response to third-line endocrine treatment for advanced breast cancer Eur J Cancer 29A 1993 572 574
31. G Brufman R Isacson N Haim Megestrol acetate in advanced breast carcinoma after failure to tamoxifen and/or aminoglutethimide Oncology 51 1994 258 261
32. M Gerritsen DJ Wagener RW Schade LV Beex Palliative chemotherapy with CMF after the same adjuvant regimen for breast cancer. The breast cancer study group Neth J Med 46 1995 131 135
33. B Hoogstraten N Gad-el-Mawla TR Maloney Combined modality therapy for first recurrence of breast cancer: a Southwest Oncology Group Study Cancer 54 1984 2248 2256
34. WM Gregory P Smith MA Richards Chemotherapy of advanced breast cancer: outcome and prognostic factors Br J Cancer 68 1993 988 995
35. MC Alonso JM Tabernero B Ojeda A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer Breast Can Res Treatment 34 1995 15 24
36. SC Fraser HJ Dobbs SR Ebbs Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs. epirubicin measuring quality of life Br J Cancer 67 1993 402 406
37. P Viladiu MC Alonso A Avella Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial Cancer 56 1985 2745 2750
38. HT Mouridsen C Rose E Engelsmann Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer: a randomized EORTC study CMF vs. CMF + Tamoxifen J Steroid Biochem 23 1985 1141 1146
39. E Petru D Schmähl On the relevance of ‘second-line’ cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations Wiener Klinische Wochenschrift 98 1986 790 797